Loading stock data…
Tonix Pharmaceuticals Holding Corp (TNXP)
$12.75-0.47 (-3.56%)
Market ClosedLast close Jun 29
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tonix Pharmaceuticals Holding Corp. in the Healthcare sector is trading at $12.75 with a market capitalization of $178M. Wall Street consensus targets $42.20 (5 analysts), implying a +231.0% move over the next 12 months. The stock is currently near its 52-week low of $10.03, remaining 22.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +231.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.88M↑ | $5.39M↑ | $3.29M↑ | $2.00M↓ | $2.43M |
| Gross Profit | $5.30M↑ | $4.33M↑ | $1.92M↑ | -$1.27M↓ | $1.49M |
| Operating Income | -$41.54M↑ | -$48.22M↓ | -$32.09M↓ | -$27.26M↓ | -$15.13M |
| Net Income | -$40.19M↑ | -$46.91M↓ | -$32.01M↓ | -$28.27M↓ | -$16.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.89%
Volume
Today's trading volume
520,255
Recent News
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Why Is TNXP Stock Rising Today?
Tonix announced a second commercial payer agreement for Tonmya, its fibromyalgia treatment.
Tonix prices 615,025 shares at $16.26 in registered direct offering
Tonix Pharmaceuticals (TNXP) entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warran
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...